Rapamycin reduces exercise benefits in older adults, study finds

6 articles · Updated · The Washington Post · Apr 29

A 13-week study led by Brad Stanfield in New Zealand involved 40 inactive adults in their 70s taking weekly low-dose rapamycin or placebo alongside home exercise.
Participants on rapamycin gained less strength and function, reported more aches and fatigue, and one developed a serious infection compared to the placebo group.
Researchers caution that the small, short-term study raises concerns about off-label rapamycin use for longevity, highlighting the need for further research on dosing, timing, and individualized effects.

This anti-aging drug made exercise less effective. Why did scientists expect the opposite?

With conflicting human trials, is rapamycin a foe to fitness or a friend to longevity?

Beyond blunting muscle gain, what hidden health risks did this rapamycin study uncover?

A major US trial is now testing rapamycin. Will it confirm these setbacks or reveal its promise?

Is timing everything? Could a different schedule unlock both anti-aging and exercise benefits?